Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage oncology company whose news flow centers on the development of TERN-701, a highly selective, oral, allosteric BCR-ABL (BCR::ABL1) inhibitor for chronic myeloid leukemia (CML). Company updates describe TERN-701 as the lead program in a focused oncology pipeline, with detailed disclosures on clinical data, regulatory interactions and trial design.
News about Terns frequently highlights results from the CARDINAL trial (NCT06163430), a global multicenter Phase 1/2 study of TERN-701 in previously treated chronic phase CML. Press releases and related SEC filings summarize major molecular response (MMR) and deep molecular response (DMR) rates, safety and tolerability findings, and outcomes in heavily pretreated or difficult-to-treat patient subgroups, including those with prior exposure to other tyrosine kinase inhibitors.
Investors following TERN can also find announcements about regulatory milestones, such as U.S. FDA Fast Track designation for TERN-701 in CML, and information on anticipated clinical priorities and program milestones. Terns’ news includes details on scientific presentations at major conferences like the American Society of Hematology (ASH) Annual Meeting and other healthcare conferences where updated CARDINAL data and development plans are discussed.
In addition, Terns issues news on capital markets activity, including underwritten public offerings of common stock intended to support research, clinical trials, development and manufacturing of key product candidates. Corporate updates may also cover decisions regarding legacy metabolic programs, such as TERN-501, TERN-801 and TERN-601, and the company’s strategy to seek partners for these assets. This news page aggregates such disclosures, offering a centralized view of Terns Pharmaceuticals’ clinical progress, financial developments and strategic focus in oncology.
Terns Pharmaceuticals (Nasdaq: TERN) announced the grant of equity inducement awards to a new employee under its 2022 Employment Inducement Award Plan. The company granted stock options to purchase 250,000 shares at an exercise price of $4.46 per share, which was the closing price on January 31, 2025. The options have a 10-year term and vest over four years, contingent on continued employment. The grant was approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4) and serves as a material inducement for the employee's acceptance of employment.
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases including oncology and obesity, has announced its upcoming participation at the 43rd Annual J.P. Morgan Healthcare Conference.
The company's management will deliver their presentation on January 15th, 2025, at 4:30 p.m. PT. Investors and interested parties can access a live webcast of the presentation through the investor relations page at http://ir.ternspharma.com. The presentation recording will remain available on the company's website for a minimum of 30 days following the event.
Terns Pharmaceuticals (Nasdaq: TERN) announced the granting of equity inducement awards to a new employee under its 2022 Employment Inducement Award Plan. The grant, approved by the Company's Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4), includes options to purchase 9,000 shares of Terns common stock.
The options come with a 10-year term and an exercise price of $5.54 per share, matching Terns' closing stock price on December 31, 2024. The options will vest over a four-year period, contingent on the employee's continued service with the company.
Terns Pharmaceuticals announced positive early data from Phase 1 CARDINAL trial of TERN-701 in patients with relapsed/refractory chronic myeloid leukemia (CML). The study showed a 50% cumulative major molecular response (MMR) rate at 3 months, with compelling molecular responses starting at lowest dose levels. The trial enrolled 15 patients across three dose levels (160mg, 320mg, 400mg) with 88% of patients showing decreased BCR-ABL levels. The drug demonstrated an encouraging safety profile with no dose-limiting toxicities or treatment discontinuations. The company expects to complete dose escalation and initiate dose expansion in 1H25, with additional efficacy data expected in 4Q25.
Terns Pharmaceuticals (Nasdaq: TERN) announced the grant of equity inducement awards to a new employee under its 2022 Employment Inducement Award Plan. The company granted options to purchase 150,000 shares of common stock with an exercise price of $6.24 per share, based on the closing price on November 29, 2024. The options have a 10-year term and vest over four years, contingent on continued employment. The grant was approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).
Terns Pharmaceuticals (Nasdaq: TERN) has appointed Heather Turner, J.D., former CEO of Carmot Therapeutics, to its Board of Directors. Turner brings 25 years of biotechnology experience, most recently leading Carmot's $3.1 billion acquisition by Roche. She replaces Ann E. Taylor, M.D., who is stepping down after three years of service. Turner's expertise spans obesity and oncology sectors, with previous leadership roles at Lyell Immunopharma, Sangamo Therapeutics, and other biotech companies. The appointment aims to strengthen Terns' strategic development of small-molecule product candidates for serious diseases.
Terns Pharmaceuticals reported Q3 2024 financial results and pipeline updates. Key highlights include expected interim data from Phase 1 CARDINAL trial of TERN-701 in CML in December 2024, and plans to initiate Phase 2 trial for TERN-601 in obesity in early Q2 2025. The company's cash position stands at $372.8 million, including a $172.7 million equity raise, providing runway into 2028. Q3 financial results show R&D expenses of $15.2 million, G&A expenses of $9.8 million, and a net loss of $21.9 million. TERN-601's Phase 1 trial demonstrated promising results with up to 5.5% weight loss over 28 days.
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for serious diseases including oncology and obesity, has announced its participation in two major investor conferences this November.
The company will participate in a fireside chat at the UBS Global Healthcare Conference on November 13, 2024, at 8:45 a.m. PT at the Terranea Resort, Rancho Palos Verdes. Additionally, they will join the Jefferies London Healthcare Conference on November 19, 2024, at 5:00 p.m. GMT at the Waldorf Hilton, London.
Live webcasts of both presentations will be available on Terns' investor relations website and archived for at least 30 days.
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company, has announced an equity inducement award for a new employee under its 2022 Employment Inducement Award Plan. The award, approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4), consists of options to purchase 20,000 shares of Terns common stock.
Key details of the stock options include:
- 10-year term
- Exercise price of $8.10 per share (closing price on October 1, 2024)
- Vesting over four years, subject to continued employment
This grant is part of Terns' strategy to attract and retain talent as it develops small-molecule product candidates for serious diseases, including oncology and obesity.
Terns Pharmaceuticals (Nasdaq: TERN) has successfully closed its previously announced public offering, raising approximately $172.7 million in gross proceeds. The offering included 14,064,048 shares of common stock at $10.50 per share and pre-funded warrants for 2,380,952 shares at $10.4999 per warrant. The underwriters fully exercised their option to purchase an additional 2,145,000 shares. Terns plans to use the net proceeds to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701, TERN-601, and the TERN-800 series, as well as for working capital and general corporate purposes. The offering was made pursuant to a previously filed registration statement and was led by Jefferies and TD Cowen as book-running managers.